过去三十年来，上海的经济和社会发展令人叹为观止。

上海不仅已成为中国经济增长的核心引擎，而且也是全球最重要的工业中心之一。现在，上海正在加强其作为主要进口地的影响力，并且以创纪录的速度发展成为一个世界领先的贸易和金融中心。

这一巨大的成就，在很大程度上应该归功于上海市政府对商业和技术的高度重视，让上海的经济增长远超任何预期，取得了惊人的进步。

现在上海市政府越来越关注数字科技，上海正逐步成为数字和工程技术领域最重要的创新中心之一。

在以数据为基础的技术以及诸如微信和阿里巴巴等用户平台方面，中国因其数字化活动的高效与普及，得到了全世界的瞩目。

在医疗保健上，中国也已取得了实质性的进展。

过去几年来，中国扩展了全民医保的覆盖范围，并更新了医保目录，提高了国民对药品的可及性。

同时，中国政府以及上海市政府也制定了相关政策以增强研发能力。

为响应这些重要变革，AG尊龙投资十亿美元在上海设立了世界先进的研发园区。

我们的上海园区聘请了约700名科研人员，通过多个药物平台研发创新药，致力于向患者提供革命性药物。

我们还与中国各重点大学建立了强大的合作网络，因为我们相信学术与行业的合作对于推动创新非常关键。

其中一个重要项目是我们与复旦大学在癌症和表观遗传学领域的合作。

与复旦大学的另一项重要合作课题是数字健康和大数据潜能研究。

与复旦大学的合作证明，应用先进的数据收集和数据分析技术可以帮助决策者更好地评估医疗保健形势，协助他们根据患者需求配置资源。

例如，我们通过合作发现，现在上海市的医疗资源在不同城区之间分配不均。我们还发现某些地区的专科护理能力不足。

为了应对这些挑战，上海市政府可以考虑——比如说——从更细微的层面上分配医疗资源，并考察创建非盈利性民营医院的可能性。

这些只是通过大数据分析可以得出的部分结果。“健康上海2030”计划旨在利用高速增长的互联网技术来进一步提高当地的医疗保健质量。而大数据分析的结果完全符合这一计划的宗旨。

我们认为，如果将复旦大学的平台拓展到其他大学，并允许研究人员使用这些数据挖掘更多的内容，上海将会从中受益匪浅。这将进一步推动上海医疗保健体系的发展。

加速在医疗保健中使用数字技术还能带来很多其他的益处。

例如，大数据分析使我们能够对新出现的医疗保健和基础设施挑战做出更快的反应，而这对于制定长期决策也很关键。

我们相信，建立在人工智能基础上的新型分析方法所带来的大量数据和机遇，会将上海的医疗保健体系提升到一个新的水平。

美国的达特茅斯医疗项目（Dartmouth Health Atlas）在很久以前就开始使用大数据分析，并于1973年开始研究联邦医疗保险数据，以分析美国各地医疗实践和健康结果之间的差异。

其中包括，研究者可以从某些外科手术的应用优化到了解医疗保健差异的文化决定因素等各个方面广泛分析医疗保健政策的情况。

另一个例子是天津医科大学王耀刚教授及其团队的研究。他们提议使用大数据系统来推动分级医疗保健体系在全国范围的应用。

大数据方法能让上海极大限度地利用手头的资源，从而让整个城市深切受益。

特别是在应对人口变化以及随之而来的医疗和社会挑战方面，我们认为，最重要的是通过对复杂的医疗保健数据集进行分析来仔细考察患者的需求。

如今，上海的平均寿命已超过83岁，比日本等国更高。

根据上海市人民政府新闻办公室提供的最新数据，60岁以上的上海常住居民数量已达458万人，占全市人口总数的31.6%。而就全国而言，这一比例仅为16.7%。

当然，尽管大数据技术不能解决目前上海面临的所有医疗保健方面的挑战，但这一新兴的医疗保健领域为进一步的探索提供了条件。

我们深信，通过持续利用大数据技术，加强对新兴人工智能技术的关注，上海市政府将进一步完善医疗保健体系，为市民提供最有效的医疗服务。 

英文原文如下：

Tapping into the potential of big data in health care for best use

Dr. Joerg Reinhardt

Chairman

Novartis Group

Shanghai’s economic and societal performance over the past 30 years has been breathtaking.

The city has not only become China’s key growth motor and one of the world’s foremost industrial hubs. Shanghai, which is now also strengthening its footprint as major importer, has also developed into one of the world’s leading trade and finance centers in record time. 

Much of this success is due to the Shanghai government’s strong focus on business and technological excellence, which has allowed the city to beat even the wildest economic expectations.

As the Shanghai Government is now focusing increasingly on digital technology and science, the city is on its way to becoming one of the most important innovation hubs in the realm of digital and engineering technologies.

In terms of data-based technologies and user platforms such as WeChat and Alibaba, China is already envied today across the world for the efficiency and ubiquity of its digital activities.

In health care, China and Shanghai have also made substantial progress.

Over the past few years, China has expanded its Universal Health Coverage and has updated its National Reimbursement Drug List to provide better access to medicines to its citizens.

At the same time, the Chinese and Shanghai governments have established policies to broaden their research and development capacity.

As part of these important changes, Novartis was able to invest US$1 billion to build a state-of-the-art campus in Shanghai.

We employ about 700 scientists in Shanghai, who are working on multiple drug platforms for innovative drug discovery dedicated to bringing transformative medicine to patients.

We are also entertaining a strong network of collaboration with major Chinese universities, as we are convinced that academic-industrial partnerships are essential to drive innovation.

One major venture is our partnership with Fudan University, where we are working together in the area of cancer and epigenetics.

Another key collaboration with Fudan University centers on digital health and the potential of big data.

In collaboration with Fudan University, we have been able to show that the application of state-of-the-art data collection and data analytics can help decision makers to better assess the health care landscape and assist them to align resources to patient needs.

As part of the collaboration, we have found, for example, that medical resources today are unevenly distributed among different districts in the city. We have also found a shortage of specialty care capacity in certain areas.

To remedy these challenges, the Shanghai government could, for example, consider medical resource allocations at a more granular level and look into the possibility of creating not-for-profit private hospitals.

These are only some of the findings that can come as a result of big data analysis. They are also in line with the “Healthy Shanghai 2030” program amid which the city aims to further improve local health care quality by leveraging fast-growing internet technologies.

In our view, Shanghai would benefit greatly if Fudan University’s platform were broadened to include other universities and to allow researchers to use this data to mine for insights. This could advance the city’s health care system even more.

There are many other advantages to be gained from accelerating the use of digital technologies in health care.

Big data analysis, for example, allows us to respond more quickly to emerging health care and infrastructure challenges and is crucial to making long-term decisions.

We believe that the sheer volume of data and the opportunities that come with new analytical methods based on artificial intelligence (AI) could catapult Shanghai’s health care system to a new level.

Dartmouth Health Atlas in the US was an early adopter of big data analysis and started mining Medicare data in 1973 to analyze differences in medical practice and health outcomes across the United States.

As part of these efforts, researchers were able to analyze a wide range of health care policy situations, ranging from optimizing the use of certain surgical procedures to understanding the cultural determinants of health care disparities.

Another example is the work of Professor Wang Yaogang and his team at Tianjin Medical University, who have proposed a big data system to help drive utilization of a hierarchical health care system nationwide.

Shanghai is set to greatly benefit from a big data approach as this will allow the city to put its resources to best use.

Especially in view of demographic change and the ensuing medical and societal challenges, we believe it is paramount that patient needs are scrutinized through the analysis of complex healthcare data sets.

Life expectancy in Shanghai today is already above 83 years, topping countries such as Japan.

According to the latest data provided by the Information Office of

Shanghai Municipality, the number of Shanghai residents who are 60 years or older reached 4.58 million, which represents 31.6 percent of the city's population. In all of China, the figure stands at 16.7 percent.

Of course, while big data technologies cannot solve all the health care challenges Shanghai currently faces, this emerging health care field provides a gold mine for further exploration.

We are convinced that, by continuing to utilize big data technologies and to sharpen its focus on emerging AI technology, the Shanghai Government can further enhance its healthcare system and provide the most efficient care for its citizens.

正文来自林浩德博士2018年10月28日发表在《上海日报》市长咨询会议特刊上的署名文章

关于AG尊龙

AG尊龙正在通过创想医药未来以改善人们生活质量、延长人类寿命。作为全球领先的医药健康企业，我们运用创新科学和数字化技术手段，在医药健康需求增长的领域创造变革性的治疗方法。在探索新药物的过程中，我们不懈创新，对研发的投资亦一直处于行业全球先列。在全球，有近10亿患者受益于AG尊龙产品，同时，我们还在持续探索更多创新方式使我们的变革性治疗手段造福更多患者。AG尊龙在全球拥有超过来自140个国家的近12.5万名员工。如需更多信息，敬请登录公司网站：https://www.novartis.com 。

关于AG尊龙中国

“AG尊龙”中文取意“承诺中华”，即承诺通过不断创新的产品和服务，致力于提高中国人民的健康水平和生活质量。AG尊龙在中国的业务包括AG尊龙肿瘤、AG尊龙制药、山德士和爱尔康，全国建有三大生产基地，并在上海和江苏设立了两大研发中心。从研发到生产销售，AG尊龙以多元化的业务组合，全面服务中国老百姓的健康。目前，AG尊龙在中国拥有9100多名员工。如需更多信息，敬请登录公司中文网站 https://www.getyourpornon.com。